{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:53:28Z","timestamp":1771462408864,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.annder.2018.11.011","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T09:47:40Z","timestamp":1548755260000},"page":"106-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France"],"prefix":"10.1016","volume":"146","author":[{"given":"A.","family":"Tournier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Khemis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Reguiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"B\u00e9gon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-C.","family":"Fougerousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Amy de la Breteque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Beneton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Parier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Boy\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Avenel-Audran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pallure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-1827","authenticated-orcid":false,"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Beauchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2018.11.011_bib0095","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2018.11.011_bib0185","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/jdv.14959","article-title":"Sex-and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u00ab OBJECTIFS PEAU \u00bb study","volume":"32","author":"Richard","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0110","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris \u2013 Update apremilast and secukinumab \u2013 EDF in cooperation with EADV and IPC","volume":"312","author":"Nast","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0115","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annder.2011.10.008","article-title":"M\u00e9thotrexate","volume":"138","author":"Beylot-Barry","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1684\/ejd.2015.2700","article-title":"Development of monoclonal gammopathy under biotherapy in psoriasis: French multicenter retrospective study","volume":"26","author":"Li\u00e9geon","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2018.11.011_bib0125","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/jdv.14406","article-title":"Factors associated with the choice of the first biologic in psoriasis: real life analysis from the Psobioteq cohort","volume":"31","author":"Sbidian","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0130","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52\u00a0week, multicentre, randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2018.11.011_bib0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/09546634.2016.1273469","article-title":"Effectiveness and safety of methotrexate in psoriasis: an 8-year experience with 218\u00a0patients","volume":"28","author":"Cabello Zurita","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.annder.2018.11.011_bib0140","doi-asserted-by":"crossref","first-page":"e0153740","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2018.11.011_bib0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2340\/00015555-2081","article-title":"Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation","volume":"96","author":"Menting","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","article-title":"Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity","volume":"25","author":"Montaudi\u00e9","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2018.11.011_bib0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjd.15305","article-title":"Determinants for drug survival of methotrexate in patients with psoriasis, split for different reasons of discontinuation \u2013 Results of the prospective MTX-CAPTUREM","volume":"177","author":"Otero","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2018.11.011_bib0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaad.2014.02.012","article-title":"Diet and psoriasis: part I. Impact of weight loss interventions","volume":"71","author":"Debbaneh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2018.11.011_bib0165","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2018.11.011_bib0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Results of a six-month, multicenter, phase IV trialrandomized, double-blind, controlled","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annder.2018.11.011_bib0175","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3899\/jrheum.130738","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"41","author":"Shea","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2018.11.011_bib0180","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM Registry","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963818312821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963818312821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:06:43Z","timestamp":1758971203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963818312821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0151963818312821"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2018.11.011","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2018.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}